Literature DB >> 25865645

Investigation of a measles outbreak in Zimbabwe, 2010: potential of a point of care test to replace laboratory confirmation of suspected cases.

A Shonhai1, L Warrener2, D Mangwanya3, R Slibinskas4, K Brown2, D Brown2, D Featherstone5, D Samuel2.   

Abstract

Blood and oral fluid (OF) samples were collected from 103 suspected measles cases between February and November 2010 during a nationwide measles outbreak in Zimbabwe. Siemens measles IgM enzyme immunoassay (EIA) on serum, Microimmune measles IgM capture EIA on OF, real-time haemagglutinin (H) gene PCR and nested nucleocapsid (N) gene PCR on OF were performed, confirming 75 measles cases. These samples were then used to evaluate a newly developed point of care test (POCT) for measles and determine its potential for identifying measles cases in outbreaks. After performing POCTs on OF samples, nucleic acid was extracted from the used test strips and the measles H and N genes amplified by RT-PCR. The sensitivity, specificity, positive and negative predictive values of the POCT for IgM in OF was 75·0% [95% confidence interval (CI) 63·4-84·5], 96·2% (95% CI 80·4-99·9), 98·2% (95% CI 90·3-100) and 58·1% (95% CI 42·1-73·0), respectively. The N gene sequences showed high level of agreement between original OF and corresponding POCT strips. Measles genotype B3 was identified in all cases. We conclude that the measles POCT has the potential to be used, at the point of contact, in outbreak situations and provide molecular characterization of the virus at a later date.

Entities:  

Keywords:  Genotype; IgM; measles; oral fluid; point of contact

Mesh:

Substances:

Year:  2015        PMID: 25865645      PMCID: PMC9150933          DOI: 10.1017/S0950268815000540

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  2 in total

1.  Measles virus strains circulating in Ethiopia in 1998-1999: molecular characterisation using oral fluid samples and identification of a new genotype.

Authors:  W Nigatu; L Jin; B J Cohen; D J Nokes; M Etana; F T Cutts; D W Brown
Journal:  J Med Virol       Date:  2001-10       Impact factor: 2.327

2.  A point-of-care test for measles diagnosis: detection of measles-specific IgM antibodies and viral nucleic acid.

Authors:  Lenesha Warrener; Rimantas Slibinskas; Kaw Bing Chua; Wondatir Nigatu; Kevin E Brown; Kestutis Sasnauskas; Dhanraj Samuel; David Brown
Journal:  Bull World Health Organ       Date:  2011-07-05       Impact factor: 9.408

  2 in total
  5 in total

1.  Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016.

Authors:  Gavin B Grant; Balcha G Masresha; William J Moss; Mick N Mulders; Paul A Rota; Saad B Omer; Abigail Shefer; Jennifer L Kriss; Matt Hanson; David N Durrheim; Robert Linkins; James L Goodson
Journal:  Vaccine       Date:  2019-03-20       Impact factor: 3.641

Review 2.  Rapid diagnostic tests to address challenges for global measles surveillance.

Authors:  David W Brown; Lenesha Warrener; Heather M Scobie; Morgane Donadel; Diane Waku-Kouomou; Mick N Mulders; Paul A Rota
Journal:  Curr Opin Virol       Date:  2020-06-29       Impact factor: 7.090

3.  Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination.

Authors:  Paul A Gastañaduy; James L Goodson; Lakshmi Panagiotakopoulos; Paul A Rota; Walt A Orenstein; Manisha Patel
Journal:  J Infect Dis       Date:  2021-09-30       Impact factor: 5.226

Review 4.  Human Ascariasis: Diagnostics Update.

Authors:  Poppy H L Lamberton; Peter M Jourdan
Journal:  Curr Trop Med Rep       Date:  2015-10-03

Review 5.  Public health responses during measles outbreaks in elimination settings: Strategies and challenges.

Authors:  Paul A Gastañaduy; Emily Banerjee; Chas DeBolt; Pamela Bravo-Alcántara; Samia A Samad; Desiree Pastor; Paul A Rota; Manisha Patel; Natasha S Crowcroft; David N Durrheim
Journal:  Hum Vaccin Immunother       Date:  2018-07-11       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.